Biotech firm CymaBay Therapeutics, Inc. revealed positive Phase 3 trial outcomes for seladelpar, a novel treatment for liver and chronic diseases, including primary biliary cholangitis. Meeting all primary and key secondary endpoints.

This article summarized the latest R&D progress of Clindamycin Phosphate, the Mechanism of Action for Clindamycin Phosphate, and the drug target R&D trends for Clindamycin Phosphate.

In autoimmune diseases, JAK inhibitors can mediate immune suppression and inhibit the increase of serum pro-inflammatory cytokines.

This article summarized the latest R&D progress of Cefuroxime Axetil, the Mechanism of Action for Cefuroxime Axetil, and the drug target R&D trends for Cefuroxime Axetil.

Adrenomed AG has disclosed recent discoveries regarding the biomarker-directed therapy of septic shock with enibarcimab.

This article summarized the latest R&D progress of Ceftazidime, the Mechanism of Action for Ceftazidime, and the drug target R&D trends for Ceftazidime.

KRAS G12D differs from KRAS G12C only in the type of amino acid mutation on the same codon.

This article summarized the latest R&D progress of Cefadroxil, the Mechanism of Action for Cefadroxil, and the drug target R&D trends for Cefadroxil.

Daiichi Sankyo has declared that the first patient has been dosed in a first-in-human Phase 1/2 examination evaluating DS-3939.

The Cannabinoid receptor 1 (CB1), as one of the most classic receptors of the Endocannabinoid system (ECS), is a G protein-coupled membrane receptor.

This article summarized the latest R&D progress of Cefaclor, the Mechanism of Action for Cefaclor, and the drug target R&D trends for Cefaclor.

VBI Vaccines Inc., a biopharma company specializing in immunology, announced that its cancer immunotherapy vaccine candidate, VBI-1901, has begun a Phase 2b trial in patients with first recurrence glioblastoma.